Maravai Lifesciences Holdings (MRVI) Common Equity (2020 - 2026)

Maravai Lifesciences Holdings' Common Equity history runs 7 years deep, the most recent figure standing at $211.6 million for Q1 2026.

• On a quarterly basis, Common Equity fell 60.1% year-over-year to $211.6 million in Q1 2026; TTM through Mar 2026 was $211.6 million, a 60.1% decrease from a year earlier, with the FY2025 full-year figure at $372.7 million, down 35.43% from the prior year.
• Common Equity declined to $211.6 million in Q1 2026 per MRVI's latest filing, from $372.7 million in the prior quarter.
• Across five years, Common Equity topped out at $905.2 million in Q4 2022 and bottomed at $211.6 million in Q1 2026.
• The 5-year median for Common Equity is $772.5 million (2024), against an average of $660.2 million.
• Across the five-year window, Common Equity jumped 206.0% in 2022 and tumbled 60.1% in 2026, its largest moves.
• Year by year, Common Equity stood at $905.2 million in 2022, then dropped by 12.74% to $789.9 million in 2023, then slipped by 26.92% to $577.2 million in 2024, then tumbled by 35.43% to $372.7 million in 2025, then plunged by 43.24% to $211.6 million in 2026.
• Per Business Quant, the three latest MRVI Common Equity figures stand at $211.6 million (Q1 2026), $372.7 million (Q4 2025), and $245.4 million (Q3 2025).